Nanomaterials Are Widely Used in Commerce, but EPA Faces Challenges in Regulating Risk

Mittal, Anu K.
June 2010
GAO Reports;6/25/2010, preceding p1
Government Documents
The article discusses nanomaterials that are widely used by companies in the U.S. It notes that a variety of products that incorporates nanomaterials already available in commerce is identified by the Government Accountability Office (GAO). The eight sectors identified are automotive, defense and aerospace, electronics and computers, energy and environment, food and agriculture, housing and construction, medical and pharmaceutical, and personal care, cosmetics and other consumer products.


Related Articles

  • policy defense.  // Hill;8/1/2011, Vol. 18 Issue 114, p26 

    The article offers news briefs on the defense policy in the U.S., including the littoral combat ship (LCS) study from the Government Accountability Office (GAO), the launch of an F-35C Joint Strike Fighter (JSF), and an accident of the airship prototype from High Altitude Research Corp.

  • Over-the-Counter Status of Medicines. Sunderland, V. Bruce // Journal of Pharmacy Practice & Research;2009, Vol. 39 Issue 2, p91 

    The article on the issuance of the behind-the-counter drug class report of the U.S. Government Accountability Office in February 2009. It states that to improve consumer access to medicines, public health and pharmacist's knowledge, the report is giving the Australian S2/S3 scheduling status to...

  • Defense Acquisitions: Assessments of Selected Weapon Programs: GAO-07-406SP. Walker, David M. // GAO Reports;3/30/2007, p1 

    This report is GAO's fifth annual assessment of selected weapon programs. From 2001 to the present, the Department of Defense (DOD) has doubled its planned investment in new systems from approximately $750 billion to almost $1.5 trillion. While DOD expects these systems to transform military...

  • About 20% of nanotech health, safety studies miss target.  // Medical Device Daily;4/30/2008, Vol. 12 Issue 84, p4 

    The article focuses on a report from the U.S. Government Accountability Office (GAO) that 20 percent of the $1.3 billion total nanotechnology research funding can not actually be attributed to this purpose. According to the National Nanotechnology Initiative (NNI), federal agencies devoted $37.7...

  • New Drug Development: Science, Business, Regulatory, and Intellectual Property Issues Cited as Hampering Drug Development Efforts: GAO-07-49. Aronovitz, Leslie G. // GAO Reports;12/19/2006, p1 

    Drug development is complex and costly, requiring the testing of numerous chemical compounds for their potential to treat disease. Before a new drug can be marketed in the United States, a new drug application (NDA), which includes scientific and clinical data, must be approved by the Food and...

  • Drug Safety: FDA Needs to Further Address Shortcomings in Its Postmarket Decision-making Process: GAO-07-599T.  // GAO Reports;3/22/2007, p1 

    GAO was asked to testify on the effectiveness of the Food and Drug Administration's (FDA) postmarket decision-making process. This testimony is based on Drug Safety: Improvement Needed in FDA's Postmarket Decision-making and Oversight Process, GAO-06-402 (March 31, 2006). The report focused on...

  • Drug Prices Going Up? Wechsler, Jill // Pharmaceutical Executive;Feb2010, Vol. 30 Issue 2, p14 

    The article reports on the increase in high prescription drug prices by the Government Accountability Office (GAO) in the U.S. It states the price increase of more than 300 drugs from 2000 to 2008 in which policymakers pointed that pharmaceutical companies lock in higher prices in expectations...

  • Update.  // Medical Marketing & Media;Jun2012, Vol. 47 Issue 6, p13 

    The article offers news briefs related to the pharmaceutical industry in the U.S. which include the deadline for the compliance of manufacturer payments, the reorganization of Pfizer Inc.'s communications team, and the report released by the Government Accountability Office (GAO).

  • Struggling with Shortages. Wechsler, Jill // Pharmaceutical Executive;Nov2011, Vol. 31 Issue 11, p12 

    The article focuses on the drug shortage crisis in the U.S. during 2010 and 2011, which is mainly due to supply chain problems in the pharmaceutical industry. The U.S. Food & Drug Administration (FDA) recorded 178 drug shortages in the U.S. in 2010, up from 157 in 2009; and three-fourths of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics